AGIO stock news

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Returns, that’s the name of the investing game. At the end of the day, investors are after the names that can help them generate a profit in the stock market. It’s as simple as that. The hard part, though, is determining which investment opportunities have the best chance of outperforming the market in the years to come. As not all stocks are created equal, Wall Street pros suggest doing some due diligence. This includes a close reading of what the analyst community has to say about the long-term growth prospects of a potential portfolio addition. Bearing this in mind, we applied this strategy to our own search for compelling investments in the healthcare space. With TipRanks’ Stock Screener tool , we used the sector, analyst consensus rating and price target upside filters to scan the market for the crème-de-la-crème. As a result, we pinpointed 3 buy-rated healthcare names that have received substantial support from Wall Street analysts. One more thing – each boasts over 30% upside potential from current levels. Read more
The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation. Read more
Agios Pharmaceuticals Inc (NASDAQ:AGIO) major shareholder Corp /De/ Celgene acquired 403,225 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were purchased at an average cost of $31.00 per share, for a total transaction of $12,499,975.00. Following the acquisition, the insider now owns 1,777,824 shares in the company, […] Read more
Agios Pharmaceuticals Inc (NASDAQ:AGIO) major shareholder Corp /De/ Celgene bought 403,225 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was bought at an average price of $31.00 per share, for a total transaction of $12,499,975.00. Following the purchase, the insider now directly owns 1,777,824 shares of the company’s stock, […] Read more
Although Agios (AGIO) betters loss estimates in Q3, its revenues lag the same. The company's wholly owned leukemia drug Tibsovo sees a rise in sales sequentially. Read more
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this event. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: … Read more
Agios' (AGIO) Tibsovo improves progression free survival and reduces risk of disease progression or death in a phase III study in previously treated patients with IDH1 mutant cholangiocarcinoma. Read more
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results from a late-stage of its lead compound tenapanor in combination with phosphate binders to treat hyperphosphatemia in patients with chronic kidney disease on dialysis) China Biologic Products Holdings Inc (NASDAQ: CBPO ) DURECT Corporation (NASDAQ: DRRX ) Insulet Corporation (NASDAQ: PODD ) ( announced private offering of convertible senior notes) Lipocine Inc (NASDAQ: LPCN ) NextCure Inc (NASDAQ: NXTC ) The Medicines Company (NASDAQ: MDCO ) (announced positive Phase 3 results for inclisiran) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 3) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aduro BioTech Inc (NASDAQ: ADRO ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Assembly Biosciences Inc (NASDAQ: ASMB ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) (announced completion of dose-escalation part of the Phase 1/2a study of AGI-134) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Gemphire Therapeutics Inc (NASDAQ: … Read more
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), … Read more
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc. Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At

ROCKIT